TITLE

Impax Laboratories initiates patent challenge relating to Generic Fentora

PUB. DATE
January 2012
SOURCE
PharmaWatch: CNS;Jan2012, Vol. 11 Issue 1, p14
SOURCE TYPE
Market Research Report
DOC. TYPE
Article
ABSTRACT
The article reports that Cephalon Inc. and CIMA Labs Inc. have filed a lawsuit against Impax Laboratories Inc. on November 18, 2011 for patent infringement with regards to the company's Fentora or fentanyl buccal tablets.
ACCESSION #
71792606

 

Related Articles

  • Cima Leaves aaiPharma for Cephalon.  // Chemical Market Reporter;11/10/2003, Vol. 264 Issue 16, p2 

    Reports on the ownership and control of the drug delivery technology platform, Cima Labs Inc. won by drug company, Cephalon Inc. over aaiPharma Inc. Terms and details of the stock purchase; Operations and financial performance of the companies; Stock price.

  • Pharmaceuticals firm to bring up to 85 new jobs to Salt Lake City. Shelton, Ryan // Enterprise/Salt Lake City;6/1/2009, Vol. 38 Issue 49, p1 

    The article reports on the decision of Cephalon Inc., a pharmaceutical company based in Frazer, Pennsylvania, to relocate its subsidiary, CIMA Labs in Brooklyn Park, Minnesota to Salt Lake City, Utah. In line with the planned relocation, Cephalon has commenced the construction of the facility...

  • Cephalon Maintains CIMA Takeout Will Fly. Cohen, Judy Radler // Mergers & Acquisitions Report;4/12/2004, Vol. 17 Issue 15, p1 

    Discusses the status of the acquisition deal between Cephalon Inc. and CIMA Laboratories Inc. Amount of money involved in the deal; Tender offer of Cephalon Inc. for the shares of CIMA; Information on the two fentanyl products from CIMA Laboratories Inc. that Cephalon Inc. wants to acquire;...

  • Biotechnology News Round-up.  // PharmaWatch: Biotechnology;December 2003, Vol. 2 Issue 12, p2 

    Reports on developments related to the biotechnology industry in the U.S. as of December 2003. Efficacy of the drug ETC-216 of Esperion Therapeutics Inc.; Deal entered by AstraZeneca PLC with Abgenix Inc.; Agreement of Cephalon Inc. to acquire Cima Labs Inc.

  • Cephalon to acquire Cima Labs for $515 million.  // PharmaWatch: Biotechnology;December 2003, Vol. 2 Issue 12, p22 

    Reports on the plan of Cephalon Inc. to acquire Cima Labs Inc. in the U.S. Value of deal; Terms under the planned acquisition; Benefits of the acquisition for both companies.

  • SDC Worldwide Mergers & Acquisitions.  // Mergers & Acquisitions Report;9/8/2003, Vol. 16 Issue 34, p6 

    Provides an update on several merger and acquisition deals of companies worldwide as of September 8, 2003. CIMA Labs Inc. and Cephalon Inc.; JNI Corp. and Applied Micro Circuits Corp.; Jacksonville Bancorp and Franklin Bank Corp.

  • ORGANON GETS FIRST EUROPEAN MARKETING APPROVAL FOR REMERON.  // Worldwide Biotech;Sep2001, Vol. 13 Issue 9, p2 

    No abstract available.

  • CIMA LABS GETS MICROEMULSION ORAL DRUG DELIVERY PATENT.  // Biotech Business;Nov2001, Vol. 14 Issue 11, p2 

    Reports on the patent issued by the United States Patent and Trademark office for a drug delivery technology of CIMA LABS Inc.

  • FDA ACCEPTS IMPAX ANDA FOR GENERIC VERSION OF CLARITIN-D.  // Biotech Business;Mar2001, Vol. 14 Issue 3, p6 

    Reports that the United States Food and Drug Administration has approved the filing of an Abbreviated New Drug Application for a generic version of Claritin-D (R) by IMPAX Laboratories Inc.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics